Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 13 Apr 2021 |
| Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab | 13 Apr 2021 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 13 Apr 2021 |
| Transactions in connection with share buy-back program | 12 Apr 2021 |
| Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer | 9 Apr 2021 |